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drugs for severe diseases to become available earlier in their development cycle but 
risks approving ineffective and/or unsafe drugs.
PCN175
A RetRosPeCtive study of PAtieNts out-of-PoCket Costs foR oRAl 
oNCology MediCAtioNs foR MultiPle MyeloMA
Rice G.
Diplomat, Flint, MI, USA
Objectives: To study patient’s out-of-pocket expenditures in patients taking oral 
oncology medication for the treatment of Multiple Myeloma who are enrolled in 
a specialty pharmacy program. MethOds: A retrospective analysis of pharmacy 
claims and reimbursement data for oncology patients enrolled in a specialty phar-
macy program and receiving biologic drugs from January 1, 2013 through October 
31, 2013 was conducted. Patients with a primary diagnosis of Multiple Myeloma 
(ICD-9 CM: 203.xx) prescription data were included. There were no exclusion criteria. 
The distribution of out-of-pocket patient’s costs per prescription were performed 
comparing average co-pay responsibility per prescription after insurance to aver-
age patient co-pay per prescription after funding assistance. Results: A total 
of 22,566 prescriptions were included. The average patient co-pay responsibility 
after insurance was $435.00 per prescription and the average patient co-pay after 
funding assistance was $81.00 per prescription. This resulted in 12,822 (91.17%) of 
the prescriptions had a patient co-pay of under $10.00 after funding assistance. 
The patient’s insurance type was as follows: private insurance was 59%, Medicare 
was 25%, Pharmacy Benefit Manager was 10%, Tricare was 1%, and Medicaid was 
5%. cOnclusiOns: In this retrospective analysis of pharmacy and financial claims 
data, Multiple Myeloma patients significantly reduced their out-of-pocket expen-
ditures, from an average of $435.00 to $81.00 by the specialty pharmacy gaining 
funding assistance for the patient.
PCN176
AssessMeNt of iMAgiNg utilizAtioN ANd tReAtMeNt PAtteRNs foR 
HeAd ANd NeCk CANCeR PAtieNts iN tHe uNited stAtes
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Objectives: To assess imaging and treatment patterns in head and neck cancer 
(HNC) patients using a large commercial-insurance database from the United States 
(U.S.). MethOds: We used the Marketscan® Research Databases (2007-2011) to 
identify adults with HNC (oral, pharynx, paranasal sinus, larynx) using ICD-9 codes. 
We evaluated three periods of imaging and treatment patterns: 1) three months 
pre-diagnosis, 2) diagnosis-to-treatment initiation, and 3) post-treatment initia-
tion. Patients receiving single-imaging modalities and multiple-imaging modali-
ties were evaluated in relation to surgery, chemotherapy, radiation therapy, and 
combinations. Imaging and treatment intensity and variability by cancer types and 
geographic regions (Northeast, North Central, South, and West) were assessed using 
multinomial and multivariate logistic regression. Results: 80,987 patients were 
analyzed (39% female, mean age: 60 years). During pre-treatment, comparing all 
cancer types to oral cancer, pharynx cancer patients had the greatest likelihood 
of single-modality imaging and multiple-modality imaging. Patients with higher 
comorbidity index scores were more likely to receive more intensive imaging prior 
to treatment. Pre-treatment imaging was more likely to occur in other regions com-
pared to West (OR range: 1.07-1.29), with consistent imaging patterns versus the 
West following treatment. There was limited regional variability in single and/or 
multiple intervention patterns. In the post-treatment period, patients receiving 
multiple treatment interventions, a proxy for advanced cancer, were more likely to 
undergo PET/CT. A high portion of larynx cancer patients received surgery (37%). 
Pharynx cancer patients were more likely to receive radiation therapy (24%) and/or 
chemotherapy (30%). During all phases combined, females were less likely to get 
imaging of any type (x-ray, CT, or PET/CT) (OR range: 0.71-0.91). cOnclusiOns: 
Commercially-insured HNC patients in the U.S. vary in imaging intensity and in the 
types of imaging modalities used, prior to and following initial diagnoses. Receiving 
multiple treatment interventions was associated with undergoing multiple imaging 
tests and more specifically, PET/CT.
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desCRiPtive ANAlysis of PAtieNts iNitiAtiNg RegoRAfeNib tHeRAPy
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Objectives: To describes treatment patterns among patients initiating regorafenib, 
an oral kinase inhibitor indicated for the treatment of metastatic colorectal cancer 
in patients who have tried other first-line therapies. MethOds: Pharmacy and 
medical claims from Humana, a large national U.S. payer, were used. The study 
sample included patients age 19 to 89 years with at least one claim for regorafenib 
between 9-27-2012 and 6-1-2013. A subset of patients with pharmacy and medical 
benefits, as well as pre-index continuous enrollment of at least 12 months, was 
used to examine prior exposure to chemotherapy, radiation, and biologic thera-
pies. Patients were followed until death, disenrollment or study end date (10-31-
2013). Results: A total of 407 patients with claims for regorafenib were identified. 
The mean age was 66.4 years, 53.1% were male, and median length of follow up was 
140 days (range of 0-357 days). Median length of pre-index continuous enrollment 
was 779 days. The majority resided in the southern (51.6%) and midwestern (26.0%) 
U.S. and most patients had Medicare Advantage (26.0%) or Medicare Part D (69.3%) 
coverage. A total of 91 regorafenib patients met all inclusion/exclusion criteria. 
Metastatic cancer diagnosis was observed in 93.4% of patients; the majority had 
liver metastases. Common pre-index comorbidities included hypertension (72.5%), 
fluid/electrolyte disorders (41.8%), chronic pulmonary diseases (25.3%), diabetes 
(34.1%), and depression (15.4%). Evidence of chemotherapy, biologic therapy, and 
PCN172
A CAll to MoNitoR dRug sHoRtAges ANd tHe Role of MARket 
AttRACtiveNess iN euRoPeAN CouNtRies
Pauwels K., Huys I., Casteels M., Simoens S.
KU Leuven, Leuven, Belgium
Objectives: Drug shortages are a global problem. While extensively studied in the 
United States, numbers about drug shortages in European countries are scarce. This 
study aims to investigate publically available data about drug shortages in European 
countries in order to reveal a typology of drug shortages in Europe. MethOds: A 
standardized reporting template was designed based on a literature search to collect 
and structure information. Countries offering an online reporting system for drug 
shortages such as Belgium, The Netherlands, England, Italy, France, Germany and 
Spain are included in this study. The online reporting systems were consulted in 
May 2013. Typology and causes of drug shortages are mapped and a sub-analysis is 
performed for essential medicines and oncology drugs. Results: Majority of drugs 
reported to suffer from shortage (n= 671) are branded (61%), oral drugs (51%) that 
equally affect different disease domains. When considering essential medicines 
(n= 200) and oncology drugs (n= 71), generics (55% for essential drugs, 64% for oncol-
ogy drugs) and injectables (52% for essential drugs, 79% for oncology drugs) are more 
involved. Causes for drug shortages are underreported, as the cause is not known 
in 66% of the cases (n= 671). Production problems are reported in 27% of the cases 
(n= 671). Results are subjected to the different scopes of the considered reporting 
systems. cOnclusiOns: Reporting of drug shortages in Europe needs to be stand-
ardized and more transparency about the reasons for drug shortages is required to 
understand the problem. A link between production problems and market attrac-
tiveness and market capacity is recognized to be at the root of drug shortages in 
U.S. Such insights are highly lacking in Europe. Monitoring of the effect of national 
and European health policies on the sustainability of the drug market is required 
to present fundamental solutions for the problem of drug shortages in Europe.
PCN173
dowNfAlls of tHe fdA ACCeleRAted APPRovAl PAtHwAy – stRiNgeNt 
CoNtRols Must be iNvoked to eNsuRe PRoMPt subMissioN of 
follow-uP CoNfiRMAtoRy tRiAl dAtA
Macaulay R.
HERON Health, London, UK
Objectives: Ponatinib was temporarily withdrawn by the FDA in October 2013 fol-
lowing safety concerns arising from its Phase III trial. This drug had previously been 
approved under the accelerated approval pathway. Three other oncologics have been 
withdrawn under similar conditions, further adding to concerns with this pathway. 
This research aims to provide an up-to-date systematic analysis of all oncolog-
ics approved under this pathway and analyse the time delay in obtaining regular 
approval. MethOds: Publically available assessments of any oncologic approved 
under the FDA accelerated approval pathway were sourced and the dates of acceler-
ated approval and conversion to regular approval were extracted. Results: 41 onco-
logics across 50 indications have been assessed under the FDA accelerated approval 
pathway, all but two of which have been approved. Of the approved indications, 50% 
(24/48) have been converted to regular approval with an average delay of 53 months 
(range 13-151 months). 6% (3/48) have been withdrawn from the market due to lack 
of efficacy and/or safety concerns arising from Phase III data. 44% (21/48) have not 
been converted to regular approval despite being on the market for an average of 
45 months (range 4–109 months). In these cases the mandatory confirmatory trials 
have not been completed and to date the FDA has not withdrawn a single oncologic 
from the market for not conducting the confirmatory trial. cOnclusiOns: 21 onco-
logic indications approved under the accelerated approval process have not been 
converted to regular approval despite some being on the market for up to 9 years. 
Given that 11% (3/27) of the drugs that have conducted confirmatory trials have been 
withdrawn, completion of confirmatory data should become a strict, non-negotiable 
requirement with a defined time limit by which the data must be submitted. A fail-
ure to do so should see the FDA automatically withdrawing their license.
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evideNCe foR A loweRed tHResHold foR fdA APPRovAl of oNCologiCs 
bAsed oN siNgle-ARM PHAse ii dAtA, CoMPARed to tHe eMA
Macaulay R.
HERON Health, London, UK
Objectives: The European Medicines Agency (EMA) approved 19 oncologics across 
25 indications on the basis of pivotal Phase II data lacking an active comparator 
(Macaulay, ISPOR Dublin 2013). Approval was typically granted for indications in 
which there was no therapeutic alternative where a response rate of ≥ 35% was 
demonstrated. This research aims to define the circumstances under which the 
Food and Drug Administration (FDA) will approve oncologics on the basis of pivotal 
Phase II data and compare to those of the EMA. MethOds: A systematic search 
was undertaken for FDA oncologic submissions based on pivotal Phase II data and 
the acceptance decision, indication, and level of benefit were extracted. Results: 
31 oncologics across 38 indications were submitted to the FDA on the basis of piv-
otal Phase II data. All of which were non-comparative and 36 were approved. This 
included all drugs approved by the EMA on this basis except trabectidin. 32 indi-
cations were approved under the accelerated approval pathway, only 47% (15/32) 
of which have been converted to regular approvals. Two of these drugs have been 
subsequently withdrawn from the market as they failed to show benefit in confirma-
tory trials (gefitinib and gemtuzumab), neither of which were EMA-approved for 
these indications. 72% (23/32) were FDA designated orphan indications. 78% (25/32) 
indications were for lines of therapy or diseases that had no relevant therapeutic 
alternatives. The response rates of approved drugs ranged from 11%-86%, while 
13 indications were approved with response rates of < 35%, which included the 
2 withdrawn drugs. cOnclusiOns: Pivotal Phase II data can support FDA onco-
logic approvals for indications that lack therapeutic alternatives and demonstrate 
response rates of ≥ 10% (versus ≥ 35% for the EMA). The lower threshold enables more 
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room visits was negatively associated with repeat mammography screening. No 
association was observed between county level characteristics such as number of 
primary care physicians, number of mammography screening facilities, and number 
of federally qualified health care centers per 10,000 women and repeat mammog-
raphy screening. cOnclusiOns: Mammography screening is underutilized in the 
Medicaid population. Various factors predicting repeat mammography screening 
were identified. Program planners should consider these factors when designing 
educational interventions aimed at increasing routine use of mammography screen-
ing among Medicaid enrollees.
PCN181
oNCology PRiCiNg tReNds iN tHe uNited stAtes ANd tHe uNited 
kiNgdoM (2011-2013)
Aggarwal S., Topaloglu H.
Novel Health Strategies, Bethesda, MD, USA
Objectives: To understand relative price differential for cancer drugs in the U.S. 
and the U.K. Develop implications for pricing strategy and patient access for cancer 
drugs. MethOds: Ten branded cancer drugs were selected and their prices for simi-
lar dose and packaging were compared in the U.S. and the U.K. Prices were analyzed 
for the end of 2011 and 2012. Historical exchange rates were used to convert British 
pounds to US dollars. Relative price discount was calculated for all selected cancer 
drugs. KOLs and payers were interviewed to understand current and future implica-
tions of this price differential. Results: The median price discount for selected ten 
branded cancer drugs in the UK versus the United States was ~50%. The range of 
discount for 10 branded cancer drugs was 27%-61%. The price discount for oral small 
molecule drugs was higher than for biologics (55% vs. 45%). Since the U.K. is one of 
the few remaining free pricing markets in Europe, other European markets are likely 
to have even higher discounts relative to the prices in the U.S. Due to rising coinsur-
ance of specialty products, U.S. cancer patients bear significantly higher costs than 
patients in the UK. KOL and payer interviews suggest U.S. pricing trends for cancer 
drugs are unlikely to be sustained at this level in the future. cOnclusiOns: U.S. 
cancer drug prices are significantly higher than the prices in the U.K. This price 
differential is unlikely to be sustained in the future.
PCN182
AN APPRAisAl of PCodR’s deCisioNs ANd iNflueNCe oveR tHe lAst 3 
yeARs
Joinnides M.1, Beckerman R.2
1CBPartners, San Francisco, CA, USA, 2CBPartners, New York, NY, USA
Objectives: The purpose of this study was to understand pCODR’s impact on pro-
vincial formulary decisions since its establishment in 2010. MethOds: 29 pCODR 
reviews were analysed. The agency publishes its reviews on its website, www.pcodr.
ca, including final recommendations for provinces to consider in their respective 
formularies. pCODR also publishes a “Provincial Funding Summary” of 9 provinces 
(all except Québec) following each of its final recommendations when available. 
pCODR’s recommendations were indexed with corresponding provincial decisions 
in order to measure the frequency with and degree to which provinces follow pCODR 
guidance. Results: Out of the 29 final recommendations analysed, pCODR has 
issued 24 positive funding recommendations, including 20 “conditional on cost-
effectiveness being improved.” Given the 24 positive recommendations, provinces 
funded products with similar or more restrictiveness than pCODR’s recommenda-
tion 21.3% of the time and with less restrictiveness 6.9% of the time; provinces 
remained under consideration, negotiation, or lacked any status update 71.8% of 
the time. No province has rejected funding of an oncology product following a 
positive pCODR recommendation. pCODR issued negative funding recommenda-
tions 5 of 29 times. Of these, provinces have almost never funded the product in 
turn. cOnclusiOns: Provinces have tended to follow pCODR’s recommendations 
or not make a decision. Compared to other provinces, Alberta tends to fund prod-
ucts with fewer restrictions than pCODR recommends, while Ontario demonstrates 
more restrictiveness. Saskatchewan has followed pCODR most closely. Manitoba, 
New Brunswick, Newfoundland and Labrador, and Prince Edward Island respond 
most slowly, in “consideration” or “negotiation” of most pCODR recommendations.
PCN183
effeCts of tHe PRiMARy PAyeR tyPe ANd RACe/etHNiCity oN PRostAte 
CANCeR sCReeNiNg PRACtiCes duRiNg PReveNtive HeAltH exAMs iN 
uNited stAtes AMbulAtoRy CARe settiNgs
Jayasekera J., Onukwugha E.
University of Maryland School of Pharmacy, Baltimore, MD, USA
Objectives: There is limited information on the relationship between insur-
ance coverage and prostate cancer(PCa)-screening practices among race/ethnic 
minorities in ambulatory care settings in the US. The objective of this study was 
to determine whether the observed race/ethnicity differences in prostate-specific 
antigen(PSA)-screening for PCa may be explained by differences in insurance 
coverage. MethOds: We analyzed a nationally representative sample of visits to 
office-based physicians’ practices from 2005-2010 using the National Ambulatory 
Medical Care Survey (NAMCS). The sample consisted of outpatient visits for preven-
tive health exams (PHEs) of men aged 40 years and above, without PCa. The primary 
insurance payer categories were mutually exclusive and included the following: 
Medicare, Medicaid, private insurance and other types. Information on the receipt 
of PSA-screening, demographics, physician specialty and type of office setting were 
collected. Generalized estimating equations were used to investigate the effect of 
race and insurance type on PSA-screening. Results: Application of the inclusion 
criteria resulted in 5,829 office-visits for PHEs. Majority (57%) of the sample was aged 
below 66 years, 10% were African Americans and 9% Hispanics. Over 47% were cov-
ered by private insurance, 39% by Medicare and 5% Medicaid. Overall, 16% received 
PSA-screening during a PHE. Hispanics (prevalence ratio:0.62,95%CI:0.43-0.90) and 
Medicaid (prevalence ratio:0.24, 95%CI:0.11-0.55) patients were less likely to receive 
PSA-screening compared to Whites and patients with private insurance. PHEs 
surgery at any time during the study period was present in 94.5%, 91.2%, and 65.9% 
of patients, respectively (5.5% of patients had no claims indicating any prior cancer 
treatment). Mean length of chemotherapy treatment was 806 days, and 571 days for 
biologic treatment. cOnclusiOns: Patients initiated on regorafenib were largely 
suffering from metastatic cancer, and had a range of comorbid conditions. Nearly 
all patients were treated with chemotherapy and/or biologic agents before initiat-
ing regorafenib treatment.
PCN178
use of boNe-ModifyiNg AgeNts followiNg ANdRogeN dePRivAtioN 
tHeRAPy foR MediCARe NoN-MetAstAtiC PRostAte CANCeR PAtieNts
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of Medicine, Baltimore, MD, USA
Objectives: Guidelines on the management of cancer treatment-induced bone 
loss (CTIBL) in men receiving androgen deprivation therapy (ADT) for prostate can-
cer (PC) recommend bisphosphonate (BP) therapy or other bone-modifying agents 
(BMAs). There is limited information on the use of BMAs for CTIBL in men with PC. 
We examined BMA utilization patterns following ADT initiation among elderly men 
with non-metastatic PC. MethOds: Using linked Surveillance, Epidemiology, and 
End Results (SEER) & Medicare data, we identified men aged 66+ with incident non-
metastatic PC diagnosed during 2007-2009, with claims from 2006-2010. Patients 
received ADT within 6 months after diagnosis and had at least 6 months of Part D 
enrollment during follow-up. Multivariable logistic regression model was estimated 
to identify demographic and clinical factors associated with BMA utilization fol-
lowing ADT initiation. Results: We identified 7,545 non-metastatic PC patients 
who received ADT (median age: 74). The sample included patients with stage 2 
(80%), 3 or 4 (8%), or unstaged (12%) PC. Overall, 8.6% had any BMA use after ADT 
initiation and the most common BMAs were oral BP (5.2%), intravenous BP (3.3%), 
followed by calcitonin (0.5%). A small proportion (1.6%) of the sample had any BMA 
use prior to ADT initiation. The median time to first BMA use after ADT initiation 
was 189 days. Factors associated with statistically significant increased likelihood 
of BMA use were older age, poorly differentiated tumor, and presence of osteo-
porosis. Compared to stage 2 PC patients, those with stages 3 or 4, and unstaged 
PC were more likely to receive BMA (p< 0.01). Patient race/ethnicity, comorbidity 
profile, and history of fracture were not statistically significantly associated with 
BMA receipt. cOnclusiOns: Less than 10% of elderly men diagnosed with non-
metastatic PC and initiating ADT received any BMA, suggesting that a significant 
gap remains in the prevention and treatment of CTIBL in this population.
PCN179
tHe dowNwARd tReNd iN oNCology dRug PRiCiNg, sPeed to MARket 
ANd ACCess
Colasante W.1, Alexander R.1, Clark J.1, Hickson S.1, Li X.2
1IMS Consulting Group, Cambridge, UK, 2University of Cambridge, Cambridge, UK
Objectives: Quantify the price, time and volume concessions incurred by manu-
facturers launching new oncology drug treatments across the EU5 in order to gain 
market access MethOds: We analyzed launches of innovative oncology products 
in both the US and EU5 since 2005 (n= 23). Two cohorts (2005-08; 2009-2013) were 
defined where we analyzed price, volume and access time. We created an overall 
opportunity index combining these 3 variables. Prices (MSP – Midas) were made rela-
tive to the US price. Time to access: 2 points were measured – time from regulatory 
approval to price approval by authorities where applicable and time to first reported 
sales. Volume was assessed as units sold over the period cohort, normalized by the 
local epidemiology Results: Price, time to access and volume are all worsening 
for all EU markets compared to the US. The overall combined opportunity index has 
declined or remained low and flat in France (1.22 – 0.93), Germany (0.80 – 0.75), Italy 
(0.45 – 0.46), Spain (0.67 – 0.39) and UK (0.54 – 0.57). US = 1. cOnclusiOns: Ongoing 
EU health care budget management have been modifying the relative commercial 
attractiveness compared to the US of many products including new oncology com-
pounds in Europe. The EU empirical mindset of trading off price to gain faster access 
to market with no or minimal concession on the usage is not supported by the data. 
For a health care perspective, the under usage of oncology products potentially and 
directly impacting overall survival of the patient compared to the US may potentially 
lead to a lower survival in EU compared to the US. Epidemiologists may only able to 
detect this consequence in the coming years.
PCN180
fACtoRs AssoCiAted witH RePeAt MAMMogRAPHy sCReeNiNg iN tHe 
MediCAid PoPulAtioN
Mahabaleshwarkar R.1, Khanna R.1, Banahan B.F.1, West-Strum D.1, Yang Y.1, Hallam J.2
1University of Mississippi, University, MS, USA, 2Kent State University, Kent, OH, USA
Objectives: Limited information currently exists regarding use of routine mam-
mography screening among Medicaid enrollees. The current study determined 
the prevalence of repeat mammography screening and the associated factors in 
the Medicaid population. MethOds: The 2006-2008 Medicaid Analytic Extract 
(MAX) data for 39 states in the United States were used in this study. The target 
population consisted of female recipients aged 40-64 years who were continuously 
enrolled in the Medicaid program during 2006-2008. Recipients with a diagnosis 
of breast cancer were excluded from the study. Repeat mammography screening 
was defined as receipt of two successive mammograms during the study period 
with a gap of 10-14 months. The effect of various recipient- and county-level fac-
tors on repeat mammography screening was determined using hierarchical logistic 
regression. Results: Approximately 1.19% of the recipients received repeat mam-
mograms during the study period. The repeat mammography screening rates were 
higher in older women and those belonging to ethnic minorities than younger 
women and whites. Number of visits to physician offices and outpatient centers, 
hormone replacement therapy, and routine cervical cancer screening were positively 
associated with repeat mammography screening. However, number of emergency 
